24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

5536 General Poster Session (Board #21D), Sat, 1:15 PM-5:15 PM<br />

Gingival cancer: 11 year follow-up at Karolinska University Hospital (2000-<br />

2010). Presenting Author: Rusana Simonoska, Department <strong>of</strong> ENT, Karolinska<br />

Institutet/Karolinska University Hospital, Stockholm, Sweden<br />

Background: In Sweden, approximately 500-600 cases <strong>of</strong> oral cancer are<br />

diagnosed every year. These include cancer <strong>of</strong> the gingiva, retromolar<br />

trigonum, bucca, hard palate, tongue and floor <strong>of</strong> the mouth. Each year,<br />

around 15 cases <strong>of</strong> gingival cancer (GC) are diagnosed in the Stockholm<br />

region. The goal <strong>of</strong> this study was to study the onset <strong>of</strong> symptoms,<br />

treatment, prognosis, and sequelae <strong>of</strong> GC in order to optimize the<br />

treatment. Methods: The study consists <strong>of</strong> a retrospective review <strong>of</strong> medical<br />

records <strong>of</strong> all diagnosed cases <strong>of</strong> GC in Stockholm region between<br />

2000-2010, identified through the ENT-clinic Karolinska Hospital patient<br />

database. Results: Our retrospective study comprised 156 patients diagnosed<br />

with GC. The average age was 72 years sharing equally between the<br />

sexes, 50% were smokers. 98% had a squamous cell carcinoma (scc).<br />

Presenting symptoms were <strong>of</strong>ten lump or ulceration in the gums, pain,<br />

bleeding or discomfort/misfit <strong>of</strong> dentures. Around 30% had premalignant<br />

lessons in the oral cavity before diagnosis. 3/4-th <strong>of</strong> all GC was localized in<br />

the lower jaw. 66% <strong>of</strong> the GC-patients presented as aT4 cancer. At<br />

presentation, 26% had a regional metastasis and <strong>of</strong> those 90% had their<br />

primary tumor in the lower jaw. Six cases had bilateral neck disease. 81%<br />

<strong>of</strong> the patients with regional metastasis had low to medium grade <strong>of</strong> scc<br />

differentiation <strong>of</strong> the primary tumor. 84% <strong>of</strong> all patients with regional<br />

metastasis had a T4 primary tumor. Neck dissection was performed in 38%<br />

(n�59). Of these 35 cases where staging neck, i.e. N0 at presentation and<br />

in 7 cases (20%) a positive neck disease was found. The risk for second<br />

primary was 15%. The overall 5-year survival was 24%. Conclusions:<br />

Advanced age and high number <strong>of</strong> T4 cancer at diagnosis partly explains<br />

the poor survival statistics. Almost 30% <strong>of</strong> the patients in our material have<br />

had premalignant lessons in the oral cavity before the cancer diagnosis and<br />

are at high risk for new tumors (second primary); therefore patients with GC<br />

should be followed up for at least 5 years, possibly longer in the presence <strong>of</strong><br />

premalignant lessons. GC <strong>of</strong> the lower jaw is more likely to metastasize than<br />

GC <strong>of</strong> the upper jaw. Due to 20% occult metastasis occurrence in the<br />

staging neck cases, we recommend staging neck dissection for patients<br />

with GC.<br />

5538 General Poster Session (Board #21F), Sat, 1:15 PM-5:15 PM<br />

A phase II study <strong>of</strong> sorafenib in combination with cisplatin and 5-fluorouracil<br />

in the treatment <strong>of</strong> recurrent or metastatic nasopharyngeal carcinoma.<br />

Presenting Author: Cong Xue, Sun Yat-sen University Cancer Center,<br />

Guangzhou, China<br />

Background: Nasopharyngeal carcinoma (NPC) is a disease with distinctive<br />

epidemiology and clinical behavior compared with Head and neck cancer<br />

(HNC) and more common in South-East Asia. Sorafenib monotherapy has<br />

been shown modest anticancer activity in HNC and NPC (C Elser et al; JCO<br />

2007). This study was to evaluate the efficacy and tolerability <strong>of</strong> sorafenib<br />

combined with cisplatin and 5-fluorouracil (5-FU) for patients with recurrent<br />

or metastatic NPC. Methods: A phase II, single arm clinical trial was<br />

conducted in three centers in China. Chemotherapy-naive histologically<br />

confirmed NPC patients with recurrent or metastatic disease were enrolled.<br />

Patients received oral sorafenib 400mg bid continuously until disease<br />

progression or unacceptable toxicity, cisplatin 80mg/m2 intravenously (iv)<br />

on day 1-5, and 5-FU 400mg/m2 iv infusion for 96 hours on day 1.<br />

Treatment was repeated every 21 days for a maximum <strong>of</strong> 6 cycles. Results:<br />

54 patients were enrolled. Most patients were with bone metastases<br />

(70.0%), followed by liver (56%) and lung metastases (56%). The median<br />

chemotherapy administrated was 4.0 cycles (range, 2-6cycles). The<br />

disease control rate (DCR) reached 90.7%, including one complete<br />

response (CR), 41 partial responses (PR) and 7 stable diseases (SD).<br />

Median PFS was 7.2 months (95% CI 6.8-8.4 months) and median OS was<br />

11.8 months (95% CI 10.6-18.7 months). Tumor cavitation after treatment<br />

was observed in 32.1% <strong>of</strong> patients with lung metastases. Decreased<br />

percentage <strong>of</strong> contrast update in responder patients (PR and CR) with liver<br />

metastases was also observed by Contrast-Enhanced Doppler ultrasound.<br />

The major toxicities include hand foot syndrome (HFS), myelo-suppression<br />

and gastrointestinal reaction.Dose reduction <strong>of</strong> sorafenib was required in<br />

22 patients (40.7%) and dose interruption in 14 patients (25.9%) because<br />

<strong>of</strong> toxicity. Conclusions: Sorafenib combined with cisplatin and 5-FU has an<br />

encouraging efficacy pr<strong>of</strong>ile with tolerable toxicity. Further randomized<br />

studies are needed to confirm the clinical benefit <strong>of</strong> sorafenib combined<br />

with chemotherapy in recurrent or metastatic NPC.<br />

Head and Neck Cancer<br />

365s<br />

5537 General Poster Session (Board #21E), Sat, 1:15 PM-5:15 PM<br />

Efficacy <strong>of</strong> concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin<br />

(5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation<br />

therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC).<br />

Presenting Author: Lauren Quinn Shapiro, Memorial Sloan-Kettering Cancer<br />

Center, New York, NY<br />

Background: We reported inferior outcomes for LAHNSCC patients (pts)<br />

that received concurrent C225 vs. high-dose CDDP with IMRT (IJROBP<br />

2011; 81:915). Prior to FDA approval <strong>of</strong> C225 for LAHNSCC, non-CDDP<br />

candidates at our institution were treated with 5FU/CBDCA (JNCI 1999;<br />

91:2081). The purpose <strong>of</strong> this study was to compare the outcomes <strong>of</strong><br />

concurrent C225 vs. 5FU/CBDCA vs. CDDP with IMRT for LAHNSCC.<br />

Methods: Retrospective review <strong>of</strong> records was performed for pts treated at<br />

MSKCC with concurrent C225 (n�49) vs. 5FU/CBDCA (n�52) vs. highdose<br />

CDDP (n�259) and IMRT from 11/02 to 04/08. Overall survival (OS),<br />

locoregional failure-free survival (LRFS), and late toxicity for all pts and<br />

oropharyngeal subset were obtained. Outcomes were analyzed using<br />

univariate/multivariate Cox proportional hazards model or competing-risks<br />

analysis. Multivariate OS analysis was confirmed by propensity score<br />

adjustment. Results: Pts were similar with regard to site, overall stage, and<br />

alcohol/tobacco history. Compared to pts treated with CDDP, those who<br />

received C225 or 5FU/CBDCA were older, with lower performance status,<br />

higher Charlson score, higher T stage, and worse renal function. With<br />

median follow-up <strong>of</strong> 53.1 months for survivors, the 4-year OS was 40.9%<br />

(95% CI 26.0-55.2%) for C225 vs. 70.2% (95% CI 55.5-80.9%) for<br />

5FU/CBDCA vs. 86.9% (95% CI 82.0-90.6%) for CDDP. Compared with<br />

CDDP, C225 (hazard ratio [HR] 4.01, p�0.0001) but not 5FU/CBDCA (HR<br />

1.54, p�0.15) was associated with worse OS on multivariate analysis.<br />

Propensity score analysis yielded a HR <strong>of</strong> 2.76 (p�0.01) for treatment with<br />

C225 vs. platinum-based chemotherapy. 4-year actuarial LRF for 5FU/<br />

CBDCA was similar to CDDP (9.7% vs. 6.3%, HR 1.51, p�0.42 by Gray’s<br />

method) and significantly lower than C225 (40.2%, HR 4.95, p�0.002).<br />

Late toxicity was as follows: C225 (6.1%) vs. CDDP (7.7%) vs. 5FU/CBDCA<br />

(21.2%). Conclusions: After adjusting for independent risk factors, there<br />

was no significant difference in OS or LRFS between 5FU/CBDCA and<br />

high-dose CDDP, but C225/RT resulted in significantly inferior OS and<br />

LRFS. Late toxicity was worst with 5FU/CBDCA.<br />

5539 General Poster Session (Board #21G), Sat, 1:15 PM-5:15 PM<br />

Patterns <strong>of</strong> care in elderly patients with squamous cell carcinoma <strong>of</strong> the<br />

head and neck: A SEER-Medicare analysis. Presenting Author: Noam<br />

Avraham Vanderwalde, Department <strong>of</strong> Radiation Oncology, University <strong>of</strong><br />

North Carolina at Chapel Hill, Chapel Hill, NC<br />

Background: Head and neck squamous cell carcinoma (HNSCC) is predominantly<br />

a disease <strong>of</strong> the elderly, however age and co-morbidity may affect<br />

therapy decisions. The purpose <strong>of</strong> this study was to assess the patterns <strong>of</strong><br />

care <strong>of</strong> elderly HNSCC patients and identify factors associated with<br />

non-receipt <strong>of</strong> surgery and chemoradiation (CRT). Methods: Using the<br />

Surveillance, Epidemiology, and End Results (SEER)-Medicare linked<br />

database (1992-2007) we identified a retrospective cohort <strong>of</strong> nonmetastatic<br />

HNSCC patients and categorized them into treatment cohorts.<br />

Comparisons were made between surgery vs. non-surgery, and CRT vs.<br />

non-CRT cohorts. Multivariate logistic regression models examined factors<br />

associated with non-receipt <strong>of</strong> treatment. Variables included tumor location,<br />

stage, year <strong>of</strong> diagnosis, age, gender, marital status, race, comorbidity,<br />

race-comorbidity interaction, SEER region, socioeconomic variables,<br />

and hospital affiliations. Results: The final cohort <strong>of</strong> 11,336 were 63%<br />

male and 83% white. 52% had no co-morbidities, 44% had oral cavity<br />

HNSCC, 52% were diagnosed between 2002 and 2007, 58% had surgery,<br />

and 21% received CRT. For the CRT vs. non-CRT model, increasing age<br />

(OR � 0.93; 95% CI 0.92 -0.94) and non-whites with co-morbidity (OR �<br />

0.71; 95% CI 0.55 – 0.92) were associated with decreased likelihood <strong>of</strong><br />

receiving CRT. More advanced staged disease, oropharyngeal tumor location,<br />

and diagnosis after 2002 were associated with increased likelihood <strong>of</strong><br />

receiving CRT. For the surgery versus non-surgery model, age was not<br />

associated with receipt <strong>of</strong> surgery (OR 0.99; 95% CI 0.99-1.00), nor was<br />

existence <strong>of</strong> comorbidity in white patients (OR 0.97; 95% CI 0.88-1.05).<br />

However, recent year <strong>of</strong> diagnosis, non-oral cavity tumor location, and<br />

advanced stage were all associated with reduced likelihood <strong>of</strong> receiving<br />

surgery. During the 15 year surveillance period, patients were less likely to<br />

receive surgery, and CRT was used more <strong>of</strong>ten. Conclusions: Age may<br />

influence the non-receipt <strong>of</strong> CRT in this elderly cohort but does not appear<br />

to be significantly associated with the non-receipt <strong>of</strong> surgery. There has<br />

been an increasing trend in the receipt <strong>of</strong> CRT with a decrease in surgery<br />

over the past 15 years.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!